- Home
- OMCL vs IMNM Comparison
OMCL vs IMNM Comparison
Compare OMCL & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OMCL | IMNM |
|---|---|---|
| Founded | 1992 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | 2001 | 2020 |
Fundamental Metrics
Financial Performance| Metric | OMCL | IMNM |
|---|---|---|
| Price | $45.77 | $22.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $43.00 | $31.44 |
| AVG Volume (30 Days) | 654.3K | ★ 2.9M |
| Earning Date | 02-05-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $1,177,740,000.00 | $9,679,000.00 |
| Revenue This Year | $8.61 | N/A |
| Revenue Next Year | $4.22 | $11.53 |
| P/E Ratio | $107.61 | ★ N/A |
| Revenue Growth | ★ 10.67 | N/A |
| 52 Week Low | $22.66 | $5.15 |
| 52 Week High | $47.69 | $25.30 |
Technical Indicators
Market Signals| Indicator | OMCL | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 70.46 | 61.19 |
| Support Level | $44.99 | $19.37 |
| Resistance Level | $47.21 | $25.30 |
| Average True Range (ATR) | 1.84 | 1.48 |
| MACD | 0.04 | 0.07 |
| Stochastic Oscillator | 82.20 | 54.24 |
Price Performance
Historical ComparisonAbout OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.